New combo targets Hard-to-Treat lung cancers after first therapy fails
NCT ID NCT05616624
First seen Nov 20, 2025 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tests a new three-drug combination (ADI-PEG 20, gemcitabine, and docetaxel) in people with small cell or non-small cell lung cancer whose disease has worsened after initial treatment. The first part of the study finds the safest dose, and the second part checks how well the combination shrinks tumors or keeps them stable. About 31 participants are expected to enroll.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.